NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

McKesson and Cardinal Health Extend CVS Drug Supply Deals Through 2032

BofA kept Buy ratings, calling the news a clearing event.

McKesson and Cardinal Health Extend CVS Drug Supply Deals Through 2032
Photo by Connor Gan on Unsplash
Already have an account? Sign in.
Featured/ 10/01/2026 · 10:31 AM
CAH
/ Don’t stop at just one post.

Related↓

Cardinal Health Beats Expectations, Raises 2026 Profit Outlook on Strong Drug Sales
10/30/2025 · 8:08 AM

Cardinal Health Beats Expectations, Raises 2026 Profit Outlook on Strong Drug Sales

Cardinal Health increases annual profit forecast to $9.65-$9.85 per share after exceeding Q1 expectations, driven by specialty medicines and branded drug demand.

/ Subscriber only
/ Read more

Feed↓

Wave Life Sciences Aligns With FDA on Single Registrational Trial for WVE-006 in AATD
10/01/2026 · 12:41 PM

Wave Life Sciences Aligns With FDA on Single Registrational Trial for WVE-006 in AATD

Wave plans a single two-year trial for WVE-006 in AATD after FDA feedback, with a one-year review for possible accelerated approval.

/ Subscriber only
Google wins dismissal of Chegg and Penske lawsuits over AI Overviews
10/01/2026 · 11:55 AM

Google wins dismissal of Chegg and Penske lawsuits over AI Overviews

A federal judge dismissed Chegg and Penske antitrust suits over Google AI Overviews, saying expected search traffic is not a contract.

/ Subscriber only
Synopsys Raises the Growth Bar at Investor Day as Wall Street Lifts Price Targets
Featured/ 10/01/2026 · 10:06 AM

Synopsys Raises the Growth Bar at Investor Day as Wall Street Lifts Price Targets

Synopsys sees mid-teens revenue growth through 2030 and margins near 50%, while average analyst targets imply about 30% upside.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe